Denali Capital Acquisition Corp. Files Q2 2025 10-Q

TL;DR

Denali Capital Acquisition Corp. filed its Q2 2025 10-Q on Aug 15, 2025. Financials are in.

AI Summary

Denali Capital Acquisition Corp. filed its 10-Q for the quarterly period ended June 30, 2025. The company, incorporated in the Cayman Islands with its principal executive offices in New York, NY, is involved in the Pharmaceutical Preparations industry. The filing was made on August 15, 2025, under SEC file number 001-41351.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Denali Capital Acquisition Corp. during the second quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing financial information, not indicating immediate significant risk.

Key Numbers

• 001-41351 — SEC File Number (Identifies the company's filings with the SEC.)
• June 30, 2025 — Quarter End Date (Marks the end of the reporting period for this 10-Q.)
• August 15, 2025 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Denali Capital Acquisition Corp. (company) — Registrant
• June 30, 2025 (date) — Quarterly period end date
• August 15, 2025 (date) — Filing date
• 001-41351 (dollar_amount) — SEC File Number
• 437 Madison Avenue, 27th Floor New York, New York 10022 (company) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ent Class A ordinary shares, par value $0.0001 per share DECA OTCQB Warrants, each wh
• $11.50 — ordinary share at an exercise price of $11.50 per share DECAW OTCQB Indicate by che

Filing Documents

• ea0251993-10q_denali.htm (10-Q) — 643KB
• ea025199301ex31-1_denali.htm (EX-31.1) — 12KB
• ea025199301ex31-2_denali.htm (EX-31.2) — 12KB
• ea025199301ex32-1_denali.htm (EX-32.1) — 4KB
• ea025199301ex32-2_denali.htm (EX-32.2) — 4KB
• 0001213900-25-077047.txt ( ) — 4897KB
• deca-20250630.xsd (EX-101.SCH) — 43KB
• deca-20250630_cal.xml (EX-101.CAL) — 19KB
• deca-20250630_def.xml (EX-101.DEF) — 237KB
• deca-20250630_lab.xml (EX-101.LAB) — 382KB
• deca-20250630_pre.xml (EX-101.PRE) — 242KB
• ea0251993-10q_denali_htm.xml (XML) — 542KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION 1 Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - DENALI CAPITAL ACQUISITION CORP. 1 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28 Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 36

OTHER INFORMATION

Part II. OTHER INFORMATION 37 Item 1. LEGAL PROCEEDINGS. 37 Item 1A.

RISK FACTORS

RISK FACTORS 37 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. 37 Item 3. DEFAULTS UPON SENIOR SECURITIES. 37 Item 4. MINE SAFETY DISCLOSURES. 37 Item 5. OTHER INFORMATION 37 Item 6. EXHIBITS. 38

SIGNATURES

Part III. SIGNATURES 39 i This report, including, without limitation, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including with respect to our proposed business combination with Semnur (as defined below) . In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about: our ability to select an appropriate target business or businesses; our ability to complete our initial business combination, including our proposed business combination with Semnur Pharmaceuticals, Inc. ("Semnur"); our expectations around the performance of the prospective target business or businesses; our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; our potential ability to obtain additional financing to complete our initial busines

Business

Business Combination The Company will provide the holders of the outstanding Public Shares (the "Public Shareholders") with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to the consummation of the initial Business Combination (initially anticipated t

View Full Filing

View this 10-Q filing on SEC EDGAR